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CASE REPORT
Refractory myeloid sarcoma with a 
FIP1L1-PDGFRA rearrangement detected 
by clinical high throughput somatic sequencing
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Abstract 
Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found 
in patients’ tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches 
based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene 
testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this princi-
ple with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic 
regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient 
was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the 
rearrangement was initially detected.
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Background
As cancer therapeutics increasingly target molecu-
lar alterations, testing for somatic changes in cancer 
is becoming an integral part of pathology evaluations. 
While these somatic alterations may only be present 
in a small subset of a given tumor type, patients with 
these genetic changes often show dramatic responses 
when treated with targeted agents [1, 2]. Single gene 
assays evaluating genes such as EGFR in lung adenocar-
cinoma or BRAF in melanoma are now performed rou-
tinely. However, a more comprehensive tumor profiling 
approach has the advantage of potentially identifying a 
breadth of actionable genetic alterations [3, 4]. Moreo-
ver, these gene panels for somatic testing can identify 
unexpected genetic changes in cancer types not generally 
associated with a given somatic alteration.
At the Center for Advanced Molecular Diagnostics 
(CAMD) at Brigham and Women’s Hospital, a targeted 
next generation sequencing assay (OncoPanel) is per-
formed in a Clinical Laboratory Improvement Amend-
ments-certified laboratory to detect somatic mutations, 
copy number variations, and structural variants across 
300 cancer-associated genes. For all patients presenting 
to Dana Farber Cancer Institute who are likely to require 
systemic therapy, informed consent is obtained, tumor 
adequacy is assessed, and Oncopanel is run to obtain a 
somatic profile for the patient’s cancer.
Here, we report a case of a 33-year-old man with 
myeloid sarcoma that was refractory to six different 
chemotherapy regimens. His tumor was analyzed using 
OncoPanel, and a FIP1L1-PDGFRA rearrangement 
was detected. As hematologic malignancies with this 
rearrangement are known to be responsive to imatinib 
therapy, he was placed on imatinib as soon as the rear-
rangement was reported. He responded rapidly to this 
course of treatment and currently shows no evidence of 
residual disease. This case is an example of an unantici-
pated finding detected through clinical high throughput 
somatic sequencing that tremendously affected a patient’s 
care and outcome.
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Case presentation
Clinical presentation
The patient is a 33-year-old man who was initially diag-
nosed at an outside hospital with a peripheral T cell lym-
phoma, based upon a supraclavicular lymph node biopsy. 
He failed to respond to a regimen of CHOP, and then did 
not respond to a course of EPOCH. Another lymph node 
biopsy was performed, and the biopsy showed myeloid 
sarcoma that was FLT3 ITD and NPM1 mutation nega-
tive. He was then transferred to our institution, where a 
CBC revealed a WBC count of 10.1 K with 9 % lympho-
cytes, 2 % eosinophils, 3 % basophils, 1 % atypical forms 
and no circulating blasts. A biopsy of a left neck lymph 
node was performed and flow cytometry found that 10 % 
of the cells were phenotypically were positive for CD34, 
CD45(dim), HLA-DR, CD56, CD34, and myeloid mark-
ers CD13, CD33, and CD117, and negative for TdT, 
CD11b, CD15, and other monocytic, B and T lymphoid 
markers, consistent with myeloblasts. Surgical pathol-
ogy sections showed a diffuse proliferation of interme-
diate to large mononuclear cells with round to irregular 
nuclei, dispersed chromatin, distinct nucleoli, and small 
amounts of cytoplasm, consistent with blast forms. Addi-
tionally, admixed plasma cells, small lymphocytes and 
abundant eosinophilic forms were noted (Fig. 1). Cytoge-
netics showed trisomy 8, and a diagnosis of myeloid 
sarcoma was rendered. A regimen of 3 days of daunoru-
bicin and 7  days of cytarabine was started, but a follow 
up PET-CT 4 weeks after initiation of treatment showed 
progressive disease. He was switched to high dose ARA-
C, but again his tumor progressed on PET-CT scan. He 
then received clofarabine and cytarabine as fifth-line 
treatment, but his disease continued to progress (Fig. 2), 
and he was switched to decitabine therapy. His CBC then 
revealed pancytopenia with 6  % circulating blasts, 6  % 
atypical forms, and 0  % eosinophils. While the patient 
was receiving decitabine, the OncoPanel testing of a left 
neck lymph node was resulted.
OncoPanel next generation sequencing
The OncoPanel assay is designed to capture and 
sequence all coding exons of 300 cancer-associated 
genes and 91 selected introns across 30 genes for rear-
rangement detection. Sequencing protocols, infor-
matics pipeline, and copy number variation detection 
were described previously [5]. Targeted next genera-
tion sequence analysis by OncoPanel detected 6 het-
erozygous single nucleotide variants or small insertions/
deletions, including KRAS c.38G>A p.G13D, ARID1B 
c.165_177CCAGCAGCAGCAG>C p.QQQQ68del, 
EPHA7 c.2042G>A p.C681Y, FANCA c.2712G>C 
p.Q904H, GATA4 c.124C>A p.P42T, and MSH6 
c.359T>C p.I120T. Copy number analysis from Onco-
panel confirmed cytogenetic findings that the patient’s 
myeloid sarcoma contained trisomy 8. Moreover, analysis 
of chromosome 4 showed a one copy loss of the 5′ end 
of PDGFRA (Fig.  3a). BreaKmer, the Oncopanel algo-
rithm that uses a ‘kmer’ strategy to assemble misaligned 
sequence reads for predicting structural rearrangements 
[6], detected discordant sequencing reads indicative of a 
FIP1L1-PDGFRA rearrangement (Fig. 3b).
FISH confirmation
On the basis of the OncoPanel findings, FISH analysis for 
FIP1L1-PDGFRA fusion was performed on interphase 
Fig. 1 Hematoxylin and eosin stained slide of left neck biopsy. A 
diffuse proliferation of intermediate to large mononuclear cells with 
round to irregular nuclei, dispersed chromatin, distinct nucleoli, and 
small amounts of cytoplasm, consistent with blast forms are seen. 
Admixed are plasma cells, small lymphocytes, and additional myeloid 
elements, including abundant eosinophilic forms
Fig. 2 Radiology showing extent of disease burden. PET-CT showing 
extensive intensely FDG-avid lymphadenopathy above and below 
the diaphragm and extensive FDG-avid skeletal/marrow disease 
burden
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and metaphase nuclei with the Vysis LSI 4q12 Tri-Color 
Rearrangement Probe Set (Abbott Molecular) that uses 
three probes (SCFD2, LNX, KIT) on chromosome band 
4q12. In this assay, FIP1L1-PDGFRA fusion is indi-
cated by isolated deletion of LNX with retention of the 
flanking SCFD2 and PDGFRA probes. Only one LNX 
hybridization signal was observed in 42/100 nuclei (42 %) 
with retention of the flanking probes, consistent with a 
FIP1L1-PDGFRA rearrangement (Fig. 3c). Moreover, the 
cells with a detected FIP1L1-PDGFRA rearrangement 
also contained trisomy 8, which was a previously demon-
strated marker of this patient’s myeloid sarcoma. Trisomy 
8 was evidenced by the presence of three signals using 
he CEP 8 Spectrum Orange DNA Probe Kit (Abbott 
Molecular), which detects chromosome 8 alpha satellite 
sequences at 8p11.1-q11.1 was used to interrogate chro-
mosome 8 copy number (Fig. 3c).
Clinical follow‑up
On the same day as the OncoPanel results were reported, 
the patient was started on 400  mg imatinib daily. Within 
1  week of initiating therapy with imatinib, his peripheral 
blast count decreased from 6 to 0 %, where it has remained. 
PET-CT performed 4 weeks later showed marked improve-
ment in the supradiaphragmatic and infradiaphragmatic 
lymphadenopathy as well as the bone marrow disease 
(Fig. 4a). This treatment response allowed him to undergo 
a reduced-intensity conditioning allogeneic stem cell trans-
plantation, and he received peripheral blood stem cells 
from his HLA-matched brother approximately 10  weeks 
after starting Imatinib. His post-transplantation course was 
relatively uneventful with mild graft-versus-host disease 
controlled with topical therapies. He is currently 9 months 
post-transplant, remains on imatinib 100 mg daily, and has 
no evidence of disease (Fig. 4b).
Fig. 3 Molecular diagnostics of the patient’s tumor. a Copy number assessment of chromosome 4 shows a one copy loss of the 5′ end of PDGFRA. 
b Translocation analysis shows the discordant reads map to intron 10 of FIP1L1 and exon 12 of PDFGRA. c Metaphase FISH analysis shows one nor-
mal copy of chromosome 4, which retains all 3 FISH probes on 4q (green SCFD2 that is centromeric to FIP1L1, orange LNX that is located between 
FIPL1 and PDGFRA, and blue KIT that is telomeric to PDGFRA). The other copy of chromosome 4 shows an isolated deletion of LNX with retention of 
the flanking SCFD2 and KIT probes, indicative of a FIP1L1-PDGFRA rearrangement. Trisomy 8 is also present in these cells, as evidenced by 3 CEP 8 
probe signals
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Conclusions
The finding of a FIP1L1-PDGFRA rearrangement in a 
patient with refractory myeloid sarcoma was an unex-
pected finding only discovered because of clinical gene 
panel testing that is performed on all malignancies pre-
senting to our institution. FIP1L1-PDGFRA was first 
discovered as a recurrent rearrangement in Hypere-
osinophilic Syndrome in 2003, and response to imatinib 
was demonstrated [7]. As the spectrum of malignan-
cies associated with this rearrangement expanded, the 
2008 WHO classification developed a category for these 
neoplasms, “Myeloid and lymphoid neoplasms associ-
ated with eosinophilia and abnormalities of PDGFRA, 
PDGFRB, or FGFR1 [8]”. Since our patient did not have 
peripheral eosinophilia, there was no indication to order 
specific testing for the FIP1L1-PDGFRA rearrangement. 
In retrospect, the initial lymph node biopsy showed a 
variety of cell types admixed with myeloblasts, including 
plasma cells, small lymphocytes, and abundant eosino-
philic forms. However, these findings alone would likely 
be insufficient to prompt single gene testing for PDG-
FRA, PDGFRB, or FGFR1.
The FIP1L1-PDGFRA fusion results in a constitutively 
activated tyrosine kinase and, in hematopoietic cells, 
results in growth factor-independent growth [7, 9]. The 
break points within FIP1L1 vary widely, but the break 
points within the PDGFRA gene are tightly clustered in 
exon 12, resulting in the disruption of the autoinhibitory 
juxtamembrane domain and activation of the kinase [10]. 
On our next generation sequencing panel, the base pair 
resolution of our translocation assay showed that this 
patient’s rearrangement occurred between intron 10 of 
FIP1L1, and exon 12 of PDGFRA. Therefore, the coor-
dinates of the rearrangement predict the disruption of 
the juxtamembrane domain and kinase activation in this 
patient.
The diagnosis of acute myeloid leukemia or myeloid 
sarcoma with a FIP1L1-PDGFRA rearrangement is 
extremely rare, with only a handful of case reports in the 
literature [11–13]. The largest case series of patients with 
AML and a FIP1L1-PDGFRA rearrangement consists 
of 5 patients, all of whom achieved complete molecular 
remission with imatinib [14]. All of the patients described 
had histories of peripheral eosinophilia, which prompted 
targeted testing for the FIP1L1-PDGFRA rearrange-
ment, since this rearrangement is cryptic and cannot 
be detected by conventional karyotype. The more wide-
spread adoption of gene panel approaches may reveal 
that this rearrangement is also present in hematologic 
neoplasms with more subtle eosinophil findings, such as 
in our case.
The importance of detecting the FIP1L1-PDGFRA 
rearrangement in hematopoetic neoplasms cannot be 
understated as this fusion protein is exquisitely sensi-
tive to imatinib. In this case, our patient had exhausted 
all conventional therapy for myeloid sarcoma and, until 
the discovery of this rearrangement by high throughput 
sequencing, was imminently terminal. As the number 
Fig. 4 Radiology evaluation of disease burden after imatinib treatment. a PET-CT 4 weeks after initiation of imatinib treatment showing marked 
interval improvement in supradiaphragmatic and infradiaphragmatic lymphadenopathy as well as the skeletal/marrow disease burden. b PET-CT 
6 months post imatinib treatment and 4 months reduced-intensity conditioning allogeneic stem cell transplantation shows no FDG-avid malig-
nancy
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of therapeutics targeting specific genetic alterations 
increases and the use of gene panel testing for somatic 
changes expands, this scenario of unanticipated findings 
dramatically affecting a patient’s clinical course is bound 
to be repeated to the benefit of cancer patients. Moreo-
ver, NGS based somatic sequencing is increasingly being 
used both to direct patients into clinical trials that target 
the specific molecular alterations found in their tumor 
and as biomarkers to associate clinical response to ther-
apy with genetic profiles [15]. The clinical utility of this 
testing might be enhanced for rare cancers or atypical 
presentations where current evidence for guiding therapy 
is limited and genomic characterizations may assist with 
treatment decisions [16]. The case report presented here 
highlights the importance of broad molecular analysis in 
cancer, especially in cases that may display atypical fea-
tures, either clinically or pathologically.
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